Stable antiviral expression (SAVE) as an approach to somatic cell gene therapy directed against HIV infection.
We are developing methods for somatic cell gene therapy directed against infection with human immunodeficiency virus by enhancing the antiviral resistance of target cells through the constitutive production of interferon-beta. Cells that have been transformed by plasmids or retroviral vectors carrying the human interferon-beta gene placed under the expression control of a murine H2Kb promoter fragment become resistant to HIV infection. Part of this enhanced resistance is due to inhibition of virus entry into the transformed cells, a hitherto unreported mechanism of interferon action.
De Maeyer
E
E
CNRS-URA 1343, Institut Curie, Centre Universitaire, Orsay, France.
Seif
I
I
Vieillard
V
V
Cases
O
O
Rousseau
V
V
De Maeyer-Guignard
J
J
Lauret
E
E
D016475:3T3 Cells; D000818:Animals; D002472:Cell Transformation, Viral; D015967:Gene Expression Regulation, Viral; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D015658:HIV Infections / Q000628:therapy*; D006801:Humans; D016899:Interferon-beta / Q000235:genetics*; D008285:Major Histocompatibility Complex / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D011401:Promoter Regions, Genetic; D012190:Retroviridae
D016899:Interferon-beta